icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
SURVEYOR-II: High SVR4 Rates Achieved With the Next Generation NS3/4A Protease Inhibitor ABT-493 and NS5A Inhibitor ABT-530 in Non-Cirrhotic Treatment-Na´ve and Treatment-Experienced Patients With HCV Genotype 3 Infection
 
 
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
 
Paul Kwo,1 Michael Bennett,2 Stanley Wang,3 Hugo E. Vargas,4 David Wyles,5 J. Scott Overcash,6 Peter Ruane,7 Benedict Maliakkal,8 Asma Siddique,9 Bal Raj Bhandari,10 Fred Poordad,11 Ran Liu,3 Chih-Wei Lin,3 Teresa I. Ng,3 Federico J. Mensa,3 Jens Kort3
 
1Indiana University School of Medicine, Indianapolis, IN, USA; 2San Diego Digestive Disease Consultants, Inc., and Medical Associates Research Group, Inc., San Diego, CA, USA; 3AbbVie Inc., North Chicago, IL, USA; 4Mayo Clinic, Phoenix, AZ, USA; 5University of California San Diego, La Jolla, CA, USA; 6eStudySite, San Diego, CA, USA; 7Ruane Medical & Liver Health Institute, Los Angeles, CA, USA; 8University of Rochester Medical Center, Rochester, NY, USA; 9Virginia Mason Hospital and Medical Center, Seattle, WA, USA;
10Gastroenterology & Nutritional Medical Services, Bastrop, LA, USA; 11Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif